New CSF Biomarkers for Alzheimer's Disease (BioAD)

Central Hospital, Nancy, France

Status: Enrolling

Conditions: Alzheimer Disease; Neurodegenerative Diseases; Dementia

Study type: Observational

Funder types: Other

Identifiers

NCT03621839

2012-PSS/COLL- LCR/ARMAND/MS

Details and patient eligibility

About

Today, the Alzheimer's disease (AD) diagnosis is founded not only on clinical criteria but also on complementary examinations to confirm a physiopathological process of AD. In complex cases, lumbar punction could be necessary in order to measure Aβ peptides and Total and phosphorylated Tau but new biomarkers could be useful. The main objective of this project is to conserve these cerebrospinal fluids, collected in usual practice in order to validate new biomarkers for diagnosis, prognosis or therapeutic following of Alzheimer's disease and other dementia.

Enrollment: 50,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Lumbar punction collected in usual practice in the context of dementia diagnosis

Exclusion criteria

• Absence of consent